There is overwhelming evidence that many delayed cutaneous adverse drug reactions (beginning >6 hours after drug intake) are mediated by delayed-type (type IV) hypersensitivity, including maculopapular eruptions, erythroderma, symmetrical drug-related intertriginous and flexural exanthema/baboon syndrome, eczematous eruptions, fixed drug eruptions, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. Therefore, after resolution of the reaction, patch tests should be performed as first diagnostic method to identify the culprit drug(s). This article provides tools to perform drug patch tests properly and safely, discussing clinical history, indications, procedure, drug patch test materials, sensitivity, the meaning of negative patch tests, and safety of the procedure. In addition, a literature review of eruptions and culprit drugs is provided in tabular format.
Get full access to this article
View all access options for this article.
References
1.
DemolyP, AdkinsonNF, BrockowK, et al.International consensus on drug allergy. Allergy, 2014; 69:420–437.
2.
BrockowK, Ardern-JonesMR, MockenhauptM, et al.EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy, 2019; 74:14–27.
3.
BrockowK, GarveyLH, AbererW, et al.Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy, 2013; 68:702–712.
4.
LehloenyaRJ, PeterJG, CopascuA, et al.Delabeling delayed drug hypersensitivity: how far can you safely go?. J Allergy Clin Immunol Pract, 2020; 8:2878–2895.e6.
5.
PhillipsEJ, BigliardiP, BircherAJ, et al.Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol, 2019; 143:66–73.
6.
De GrootAC. Monographs in Contact Allergy, Volume 4: Systemic Drugs. Boca Raton, FL: CRC Press Taylor and Francis Group; 2022. ISBN 978-0-367-43649-0.
7.
BarbaudA. Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep, 2014; 14:442.
8.
WolkensteinP, ChosidowO, FléchetML, et al.Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis, 1996; 35:234–236.
9.
BarbaudA, ColletE, MilpiedB, et al.A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol, 2013; 168:555–562.
10.
SantiagoF, GonçaloM, VieiraR, et al.Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis, 2010; 62:47–53.
11.
LinYT, ChangYC, HuiRC, et al.A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol, 2013; 27:356–364.
12.
OhtoshiS, KitamiY, SuekiH, et al.Utility of patch testing for patients with drug eruption. Clin Exp Dermatol, 2014; 39:279–283.
13.
TchenT, ReguiaïZ, VitryF, et al.Usefulness of skin testing in cutaneous drug eruptions in routine practice. Contact Dermatitis, 2009; 61:138–144.
14.
BarbaudA, Reichert-PenetratS, TréchotP, et al.The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol, 1998; 139:49–58.
15.
BarbaudA, BeneMC, FaureG, et al.Tests cutanés dans l'exploration des toxidermies supposées de mécanisme immuno-allergique [in French]. Bull Acad Natl Med, 2000; 184:47–63.
16.
OsawaJ, NaitoS, AiharaM, et al.Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol, 1990; 17:235–239.
17.
BrockowK, PfütznerW. Cutaneous drug hypersensitivity: developments and controversies. Curr Opin Allergy Clin Immunol, 2019; 19:308–318.
18.
BergmannMM, CaubetJC. Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (SCAR) to drug. Curr Pharm Des, 2019; 25:3872–3880.
19.
Ardern-JonesMR, MockenhauptM. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol, 2019; 19:283–293.
20.
BrandtO, BircherAJ. Delayed-type hypersensitivity to oral and parenteral drugs. J Dtsch Dermatol Ges, 2017; 15:1111–1132.
21.
FriedmannPS, Ardern-JonesM. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol, 2010; 10:291–296.
22.
BarbaudA. Skin testing in delayed reactions to drugs. Immunol Allergy Clin N Am, 2009; 29:517–535.
23.
RomanoA, ViolaM, GaetaF, et al.Patch testing in non-immediate drug eruptions. Allergy, Asthma Clin Immunol, 2008; 4:66–74.
24.
BarbaudA. Drug skin tests and systemic drug reactions: an update. Expert Rev Dermatol, 2007; 2:481–495.
25.
ShearN, MilpiedB, BruynzeelDP, et al.A review of drug patch testing and implications for HIV clinicians. AIDS, 2008; 22:999–1007.
26.
BarbaudA, WeinbornM, GarveyL, et al.Intradermal tests with drugs: an approach to standardization. Front Med (Lausanne), 2020; 7:156.
27.
AbererW, BircherA, RomanoA, et alEuropean Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy, 2003; 58:854–863.
28.
DemolyP, KropfR, BircherA, et al.Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy, 1999; 54:999–1003.
29.
JohansenJD, Aalto-KorteK, AgnerT, et al.European Society of Contact Dermatitis guideline for diagnostic patch testing—recommendations on best practice. Contact Dermatitis, 2015; 73:195–221.
30.
MahlerV, NastA, BauerA, et al.S3 guidelines: epicutaneous patch testing with contact allergens and drugs—short version, part 1. J Dtsch Dermatol Ges, 2019; 17:1076–1093.
31.
MahlerV, NastA, BauerA, et al.S3 Guidelines: epicutaneous patch testing with contact allergens and drugs—short version, part 2. J Dtsch Dermatol Ges, 2019; 17:1187–1207.
BaeckM, GoossensA. Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines. Contact Dermatitis, 2012; 66:38–45.
34.
SoriaA, BaeckM, GoossensA, et al.Patch, prick or intradermal tests to detect delayed hypersensitivity to corticosteroids?. Contact Dermatitis 2011;64:313–324.
35.
BelliniV, BianchiL, HanselK, et al.Bullous nonpigmenting multifocal fixed drug eruption due to pseudoephedrine in a combination drug: clinical and diagnostic observations. J Allergy Clin Immunol Pract, 2016; 4:542–544.
36.
Ozkaya-BayazitE. Topical provocation in fixed drug eruption due to metamizol and naproxen. Clin Exp Dermatol, 2004; 29:419–422.
37.
AlankoK, StubbS, ReitamoS. Topical provocation of fixed drug eruption. Br J Dermatol, 1987; 116:561–567.
38.
AlankoK. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis, 1994; 31:25–27.
39.
ÖzkayaE. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis, 1999; 41:185–189.
40.
LeeA-Y. Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis, 1998; 38:258–260.
41.
Özkaya-BayazitE, BaykalC. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol, 1997; 137:1028–1029.
42.
KleinCE, TrautmannA, ZillikensD, et al.Patch testing in an unusual case of toxic epidermal necrolysis. Contact Dermatitis, 1995; 33:448–449.
43.
BarbaudA. Drug patch testing in systemic cutaneous drug allergy. Toxicology, 2005; 209:209–216.
44.
BarbaudA, TrechotP, Reichert-PenetratS, et al.Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis, 2001; 45:265–268.
45.
BarbaudA, GonçaloM, BruynzeelD, et al.Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis, 2001; 45:321–328.
46.
LehloenyaRJ, ToddG, WallaceJ, et al.Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. Br J Dermatol, 2016; 175:150–156.
47.
AssierH, Valeyrie-AllanoreL, GenerG, et al.Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Dermatitis, 2017; 77:297–302.
48.
GrimsRH, KränkeB, AbererW. Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives. Contact Dermatitis, 2006; 54:290–294.
49.
BrajonD, MenetreS, WatonJ, et al.Nonirritant concentrations and amounts of active ingredient in drug patch tests. Contact Dermatitis, 2014; 71:170–175.
50.
BüyükYaytokgil Ş, GüvenirH, KülhaşCelík İ, et al.Evaluation of drug patch tests in children. Allergy Asthma Proc, 2021; 42:167–174.
51.
Atanasković-MarkovićM, JankovićJ, TmušićV, et al.Hypersensitivity reactions to antiepileptic drugs in children. Pediatr Allergy Immunol, 2019; 30:547–552.
52.
BarbaudA, TrechotP, Weber-MullerF, et al.Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis, 2004; 50:22–26.
53.
RomanoA, Di FonsoM, PapaG, et al.Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy, 1995; 50:113–118.
54.
SoriaA, AmslerE, BernierC, et alFISARD group. DRESS and AGEP reactions to iodinated contrast media: a French case series. J Allergy Clin Immunol Pract, 2021; 9:3041–3050.
55.
BursztejnA-C, RatA-C, TréchotP, et al.Results of skin tests to assess drug-induced allergy. Ann Dermatol Venereol, 2010; 137:688–694.
56.
LammintaustaK, Kortekangas-SavolainenO. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol, 2005; 152:968–974.
57.
TrubianoJA, DouglasAP, GohM, et al.The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. J Allergy Clin Immunol Pract, 2019; 7:1341–1343.e1.
58.
LammintaustaK, Kortekangas-SavolainonO. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Derm Venereol, 2005; 85:491–496.
59.
WatonJ, TrlechotP, Loss-AyavC, et al.Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br J Dermatol, 2009; 160:786–794.
60.
Benamara-LevyM, HaccardF, Jonville BeraAP, et al.Acute generalized exanthematous pustulosis due to acetazolamide: negative on patch testing and confirmed by delayed-reading intradermal testing. Clin Exp Dermatol, 2014; 39:220–222.
61.
JachietM, BellónN, AssierH, et al.Cutaneous adverse drug reaction to oral acetazolamide and skin tests. Dermatology, 2013; 226:347–352.
62.
AssierH, GenerG, ChosidowO, et al.Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases. Contact Dermatitis, 2021; 84:280–282.
63.
BensaidB, RozieresA, NosbaumA, et al.Amikacin-induced drug reaction with eosinophilia and systemic symptoms syndrome: delayed skin test and ELISPOT assay results allow the identification of the culprit drug. J Allergy Clin Immunol, 2012; 130:1413–1414.
64.
TrckaJ, SeitzCS, BrockerE-B, et al.Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin. J Antimicrob Chemother, 2007; 60:107–111.
65.
VaillantL, CamenenI, LoretteG. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol, 1989; 125:299.
66.
NittaY, OnouchiH. A case of drug-related eruptions due to carbamazepine with a flare from patch testing [in Japanese]. Jpn J Dermatol, 2003; 113:983–987.
67.
PapakonstantinouE, MüllerS, RöhrbeinJH, et al.Generalized reactions during skin testing with clindamycin in drug hypersensitivity: a report of 3 cases and review of the literature. Contact Dermatitis, 2018; 78:274–280.
68.
MachetL, VaillantL, DardaineV, et al.Patch testing with clobazam: relapse of generalized drug eruption. Contact Dermatitis, 1992; 26:347–348.
69.
Garcia-BravoB, RepisoJB, CamachoF. Systemic contact dermatitis due to deflazacort. Contact Dermatitis, 2000; 43:359–360.
70.
Gonzalo-GarijoMA, de ArilaD, Rodriguez-NevadoI. Generalized reaction after patch testing with metamizol. Contact Dermatitis, 2001; 45:180.
71.
EchechipíaS, AlvarezMJ, GarcíaBE, et al.Generalized dermatitis due to mitomycin C patch test. Contact Dermatitis, 1995; 33:432.
72.
MashiahJ, BrennerS. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol, 2003; 139:1181–1183.
73.
CabañasR, MuñozL, López-SerranoC, et al.Hypersensitivity to piperacillin. Allergy, 1998; 53:819–820.
74.
TombRR, LepoittevinJ-P, EspinassouzeF, et al.Systemic contact dermatitis from pseudoephedrine. Contact Dermatitis, 1991; 24:86–88.
75.
SanchezTS, Sanchez-PerezJ, AraguesM, et al.Flare-up reaction of pseudoephedrine baboon syndrome after positive patch test. Contact Dermatitis, 2000; 42:312–313.
76.
FontaineJF, LavaudF, DesleeG, et al.Toxic dermatitis caused by pseudoephedrine: apropos of a case [in French]. Allerg Immunol (Paris), 2002; 34:230–232.
77.
TeoYX, Ardern-JonesMR. Reactivation of drug reaction with eosinophilia and systemic symptoms with ranitidine patch testing. Contact Dermatitis, 2021; 84:278–279.
78.
ShebeK, NgwanyaMR, GantshoN, et al.Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. Contact Dermatitis, 2014; 70:125–127.
79.
ConilleauV, DompmartinA, VerneuilL, et al.Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis, 1999; 41:141–144.
80.
De GrootAC. Allergic contact dermatitis from topical drugs: an overview. Dermatitis, 2021; 32:197–213.
81.
De GrootAC. Monographs in Contact Allergy, Volume 3: Topical drugs. Boca Raton, FL: CRC Press Taylor and Francis Group; 2021. ISBN 978-0-367-23693-9.
